You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
迪瑞醫療(300396.SZ)業績快報:2020年度淨利潤升15.19%至2.67億元
格隆匯 03-28 16:33

格隆匯 3 月 28日丨迪瑞醫療(300396.SZ)披露2020年度業績快報,實現營業總收入9.37億元,同比下降7.09%;營業利潤3.10億元,同比增長2.05%;利潤總額3.13億元,同比增長0.99%;歸屬於上市公司股東的淨利潤2.67億元,同比增長15.19%;基本每股收益0.9744元。

報吿期內預計非經常性損益對淨利潤的影響金額約7679.86萬元主要系報吿期內處置原控股子公司寧波瑞源生物科技有限公司部分股權的投資收益6615.79萬元

報吿期內,公司營業收入略有下降,主要系轉讓原控股子公司寧波瑞源生物科技有限公司17%權,不再擁有其控制權9-12收入不再納入合併範圍所致。

報吿期內,公司克服疫情帶的國內及國際市場及物流影響,積極發揮儀器多元化的競爭優勢,調整銷售策略,抓住國家完善基礎醫療的機會,報吿期內儀器銷售比例有所上升為帶動後期試劑銷售起到積極作用。報吿期,公司向控股公司寧波瑞源生物科技有限公司小股東回售部分股權收回投資收益,增加了公司利潤的同時,為加大免疫、婦科分析為主的新品銷售力度儲備充裕的資金

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account